7 Tide Street
95 articles with Ginkgo Bioworks
Ginkgo Bioworks, Inc. and Soaring Eagle Acquisition Corp., a special purpose acquisition company, announced the closing of their previously announced business combination.
Tantu and Ginkgo Bioworks Announce Partnership to Engineer a Living Biotherapeutic for Gastrointestinal Healing
Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, announced a partnership to accelerate the research and development of Tantu's therapeutic genes.
Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.
Ginkgo Bioworks Inc., which is building the leading horizontal platform for cell programming and recently announced a business combination with Soaring Eagle Acquisition Corp., announced that management is scheduled to participate in the following upcoming conferences
Cambium Biomaterials Announces Partnership with Ginkgo Bioworks to Accelerate Industrial Adoption of High-Performance Biomaterials
Cambium Biomaterials, the company creating high-performance biomaterials, announced a partnership with Ginkgo Bioworks, Inc., which is building the leading horizontal platform for cell programming.
Ginkgo Bioworks, Inc., which is building the leading horizontal platform for cell programming, announced the signing of a multi-program collaboration with Givaudan, the world's leading Taste & Wellbeing and Fragrance & Beauty company.
Cronos Group and Ginkgo Bioworks Announce Achievement of Equity Milestone in Partnership to Produce Cultured Cannabinoids
Cronos Group, Inc. and Ginkgo Bioworks today announced the achievement of the first target productivity milestone in their partnership to produce eight cultured cannabinoids.
Ginkgo has signed multiple collaborations, announced a breakthrough in manufacturing mRNA vaccine components, and landed an SPAC deal.
Ginkgo Bioworks today announced a revenue and business update for the first half of 2021.
Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines using Synthetic Biology
Antheia and Ginkgo Bioworks today announced a partnership to accelerate the development and production of essential medicines.
Antheia has joined forces with Ginkgo Bioworks to strengthen its efforts in developing and producing essential medicines to treat a wide range of diseases.
Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines
Aldevron and Ginkgo Bioworks , Inc. ("Ginkgo") today announced a manufacturing breakthrough driven by their strategic partnership.
Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is now touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.
Ginkgo Bioworks, Inc. announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET.
8/6/2021Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
Bolt Threads to Leverage Ginkgo Bioworks' Platform for Commercial Strain Optimization of b-silk™ Protein
Bolt Threads, a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks, Inc., which is building the leading horizontal platform for cell programming, announced a partnership.
Ginkgo Bioworks, Inc. announced that Reshma Kewalramani, M.D., FASN, Chief Executive Officer and President at Vertex, will join its board of directors.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
Ginkgo Bioworks Announces R&D Collaboration with Sumitomo Chemical to Develop More Sustainable Bio-Based Chemicals for Multiple Industries
Ginkgo Bioworks, Inc. ("Ginkgo") today announced the signing of a program in a partnership with the Sumitomo Chemical Co., Ltd . ("Sumitomo Chemical"), one of Japan's leading chemical companies. Ginkgo is building the leading horizontal platform for cell programming, to serve customers across industries seeking to develop better products.
Cronos Group and Ginkgo Bioworks Amend Agreement to Accelerate Commercialization of Cultured Cannabinoids and Cronos Group Begins Commercial Production of CBG
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), an innovative global cannabinoid company, and Ginkgo Bioworks, Inc. (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced an amended collaboration and license agreement (the “Amended Agreement”) that will enable the companies to accelerate the commercialization of cultured cannabinoids at scale.